Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

[1]  R. Gelber,et al.  Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Forbes,et al.  Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Ocaña,et al.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. , 2011, Journal of the National Cancer Institute.

[4]  A. Giobbie-Hurder,et al.  Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer , 2011, Breast Cancer Research.

[5]  K. Pritchard,et al.  Long-term follow-up of women in trials of adjuvant therapy for breast cancer: is it still important? , 2011, Journal of Clinical Oncology.

[6]  István Láng,et al.  Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Schoenfeld,et al.  Correcting for discretionary treatment crossover in an analysis of survival in the Breast International Group BIG 1-98 trial by using the inverse probability of censoring weighted method. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Bonetti,et al.  Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Griggs,et al.  American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Cuzick,et al.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Giobbie-Hurder,et al.  Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. , 2009, The New England journal of medicine.

[12]  A. Giobbie-Hurder,et al.  Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer , 2009, Clinical trials.

[13]  V. Jordan.  The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Brodie,et al.  Stopping treatment can reverse acquired resistance to letrozole. , 2008, Cancer research.

[15]  J. Costantino,et al.  Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Forbes,et al.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Forbes,et al.  Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[21]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[22]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[23]  R. Gray,et al.  Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Knobf.  Early-stage breast cancer: the options. , 1990, The American journal of nursing.